PF-219,061

PF-219,061
Systematic (IUPAC) name
(R)-3-(4-propylmorpholin-2-yl)phenol
Clinical data
Routes of
administration
Nasal
Identifiers
CAS Number 710654-74-3 YesY
PubChem CID 9794475
ChemSpider 7970242
Chemical data
Formula C13H19NO2
Molar mass 221.295 g/mol
  (verify)

PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It is under development as a potential medication for the treatment of female sexual dysfunction.[3][4]

See also

References

  1. Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorganic and Medicinal Chemistry Letters. 2007 Dec 15;17(24):6691-6. doi:10.1016/j.bmcl.2007.10.059 PMID 17976986
  2. Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. Drug Discovery Today: Therapeutic Strategies. 2006;3(4):599-604. doi:10.1016/j.ddstr.2006.10.006
  3. Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer.
  4. Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica. 2009 Jul;39(7):523-33. PMID 19480558


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.